{"id":"W3083498943","doi":"10.1158/1538-7445.am2020-ct150","title":"Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Rash; Cancer; Renal cell carcinoma; Lung cancer; Melanoma; Oncology; Gastroenterology; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005702723,0.0002370431,0.0005317881,0.0002517094,0.0002638822,0.00003306415,0.0004349657,0.00007857857,0.0003221054],"category_scores_gemma":[0.0001915914,0.0001642667,0.0000744403,0.002429598,0.0003051413,0.0001126421,0.0001099011,0.001173276,0.00000433096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006884276,"about_ca_system_score_gemma":0.0007780663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003674715,"about_ca_topic_score_gemma":0.00638533,"domain_scores_codex":[0.9968092,0.0002697576,0.0005861698,0.0005518641,0.001125769,0.0006571778],"domain_scores_gemma":[0.9986184,0.0001189245,0.0001556134,0.0005156009,0.0004161641,0.0001752825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1144693,0.01256074,0.6508508,0.001318529,0.0005240962,0.0003037173,0.02932851,0.0006562257,0.1675864,0.000008714531,0.001822478,0.02057043],"study_design_scores_gemma":[0.06188169,0.008737002,0.9081069,0.0008431972,0.00002945342,0.00000273685,0.003356284,0.00007971215,0.01531878,0.000004089424,0.001384591,0.0002555216],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951351,0.0003074249,4.801338e-7,0.001292746,0.00005429243,0.002755454,0.00003392312,0.00002789611,0.0003926884],"genre_scores_gemma":[0.9990995,0.00007905393,0.000007069571,0.0001573098,0.000072366,0.0003911224,0.00001848626,0.0000535818,0.0001214968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2572562,"threshold_uncertainty_score":0.6698604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0506028019822661,"score_gpt":0.3909846976816892,"score_spread":0.3403818956994231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}